BioSpace News Archive

Affimed N.V., a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced the appointment of Dr. Constanze Ulmer-Eilfort to its Supervisory Board.

Newly published research in the journal Public Health Practice shows that a weekly program of nasal photodisinfection implemented at a major Western Canada meat packing plant, alongside standard safety measures recommended by the US Centre for Diseases Control and Prevention, reduced the expected COVID-19 positivity rate by over 99%, from 1,344 expected positive PCR tests to 3 positive PCR tests out of over 21,000 administered tests over a seven-month period.

Genelux Corporation announced that it will be added to the broad-market Russell 3000® Index and small-cap Russell 2000® at the conclusion of the 2023 Russell indexes annual reconstitution, effective after the U.S. equity markets open on June 26, 2023 according to a preliminary list of additions.

TransCode Therapeutics, Inc. announced today publication of new data relevant to its lead therapeutic candidate, TTX-MC138, in the Journal of Clinical Oncology.

Aeglea BioTherapeutics, Inc. (“Aeglea”) (NASDAQ: AGLE), today announced it has completed the acquisition of Spyre Therapeutics, Inc. (“Spyre”), a privately held biotechnology company advancing a robust pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease (IBD).

BTG Pharmaceuticals, a SERB company, highlights the recent updates to the National Comprehensive Cancer Network (NCCN) Guidelines for Acute Lymphoblastic Leukemia, B-Cell Lymphomas, Pediatric Acute Lymphoblastic Leukemia, and Pediatric Aggressive Mature B-Cell Lymphomas.

Caristo Diagnostics Limited applauds the FDA’s decision to approve colchicine as first anti-inflammatory drug for cardiovascular disease.

Kite Announces Completion of Marketing Authorization Transfer for Yescarta ® CAR T-cell Therapy in Japan.

Mind Medicine announced today that members of the Company’s management team will participate in the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference.

Promore Pharma (STO:PROMO)(FRA:8T0) STOCKHOLM, June 22, 2023 -- Promore Pharma AB comments today that a number of measures have been taken to reduce the Company’s costs, which includes the discontinuation of the ensereptide project and the termination of the Company’s key personnel.